Craig-Hallum lowered the firm’s price target on MiMedx (MDXG) to $13 from $14 and keeps a Buy rating on the shares following quarterly results. The company reiterated its 2025 guidance for high-single digit revenue growth and over 20% EBITDA margins, despite the LCD delay, the firm notes. Q1 revenue and EBITDA were in-line to slightly ahead of expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG: